4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17, 2024 at 8:49 a.m. CESTCompany to provide a high-level safety update on 4D-150 treated patients from PRISM and SPECTRA studies (N=139) Company to host webcast on Wednesday, July 17, 2024 at 6:30 a.m. ET EMERYVILLE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that the Company will present the initial interim 24-week landmark analysis from the Population Extension cohort of the PRISM Phase 2 Clinical Trial evaluatin
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $40.00 price target on the stock.MarketBeat
- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy [Yahoo! Finance]Yahoo! Finance
- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic AtrophyGlobeNewswire
- 4D MOLECULAR INVESTOR ALERT: Kaskela Law LLC Announces Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the FirmAccesswire
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting [Yahoo! Finance]Yahoo! Finance
FDMT
Earnings
- 5/9/24 - Beat
FDMT
Sec Filings
- 6/26/24 - Form 4
- 6/25/24 - Form 144/A
- 6/24/24 - Form 144
- FDMT's page on the SEC website